MERSANA THERAPEUTICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.135 USD | -0.79% |
|
-2.49% | +34.91% |
| Mar. 20 | North American Morning Briefing : Markets on Hold -2- | DJ |
| Mar. 19 | JPMorgan Upgrades Mersana Therapeutics to Neutral From Underweight, Price Target is $5 | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 274.4 | 1,823 | 447.3 | 584.7 | 279.8 | 386.7 | - | - |
| Enterprise Value (EV) 1 | 212.7 | 1,568 | 294 | 304 | 99.15 | 276.4 | 363 | 386.7 |
| P/E ratio | -8.82 x | -18.6 x | -2.58 x | -2.69 x | -1.57 x | -4.76 x | -4.38 x | -4.39 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 6.51 x | 2,201 x | 10,402 x | 22 x | 7.59 x | 9.9 x | 11.6 x | 12.3 x |
| EV / Revenue | 5.05 x | 1,893 x | 6,837 x | 11.4 x | 2.69 x | 7.08 x | 10.9 x | 12.3 x |
| EV / EBITDA | -7.35 x | -18 x | -1.75 x | -1.5 x | -0.59 x | -3 x | -3.48 x | -4.5 x |
| EV / FCF | -3.11 x | -20.9 x | -2.09 x | -6.03 x | -0.58 x | -4.13 x | -4.25 x | -4.34 x |
| FCF Yield | -32.1% | -4.8% | -47.8% | -16.6% | -173% | -24.2% | -23.6% | -23% |
| Price to Book | 3.18 x | 7.17 x | 3.77 x | 5.96 x | - | - | - | - |
| Nbr of stocks (in thousands) | 47,884 | 68,497 | 71,912 | 99,774 | 120,582 | 122,361 | - | - |
| Reference price 2 | 5.730 | 26.61 | 6.220 | 5.860 | 2.320 | 3.160 | 3.160 | 3.160 |
| Announcement Date | 2/28/20 | 2/26/21 | 2/28/22 | 2/28/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 42.12 | 0.828 | 0.043 | 26.58 | 36.86 | 39.05 | 33.24 | 31.53 |
| EBITDA 1 | -28.96 | -87.1 | -168 | -202.8 | -169.4 | -92.19 | -104.2 | -85.91 |
| EBIT 1 | -30.2 | -88.11 | -168.9 | -203.8 | -171 | -89.06 | -104.9 | -107 |
| Operating Margin | -71.69% | -10,641.3% | -392,693.02% | -766.59% | -463.86% | -228.06% | -315.57% | -339.28% |
| Earnings before Tax (EBT) 1 | -28.21 | -88.04 | -170.1 | -204.2 | -171.7 | -86.9 | -103.5 | -111.9 |
| Net income 1 | -28.21 | -88.04 | -170.1 | -204.2 | -171.7 | -83.74 | -97.68 | -111.9 |
| Net margin | -66.97% | -10,633.45% | -395,488.37% | -768.26% | -465.8% | -214.45% | -293.85% | -354.97% |
| EPS 2 | -0.6500 | -1.430 | -2.410 | -2.180 | -1.480 | -0.6633 | -0.7222 | -0.7200 |
| Free Cash Flow 1 | -68.35 | -75.17 | -140.6 | -50.42 | -171 | -67 | -85.5 | -89 |
| FCF margin | -162.26% | -9,078.38% | -327,060.47% | -189.67% | -464.12% | -171.57% | -257.21% | -282.25% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 2/28/20 | 2/26/21 | 2/28/22 | 2/28/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.011 | 0.011 | 2.036 | 4.284 | 5.573 | 14.69 | 7.802 | 10.65 | 7.698 | 10.7 | 8.502 | 8.708 | 8.879 | 9.093 | - |
| EBITDA 1 | -45.19 | -47.82 | -46.35 | -51.52 | -59.43 | -45.54 | -57.48 | -56.18 | - | -20.48 | -20.49 | -22.14 | -23.87 | -25.69 | - |
| EBIT 1 | -45.4 | -48.03 | -46.55 | -51.75 | -59.64 | -45.83 | -57.8 | -56.5 | -35.73 | -20.93 | -23.25 | -23.85 | -24.55 | -25.41 | - |
| Operating Margin | -412,718.18% | -436,645.45% | -2,286.44% | -1,207.98% | -1,070.14% | -312% | -740.85% | -530.33% | -464.11% | -195.57% | -273.44% | -273.92% | -276.54% | -279.45% | - |
| Earnings before Tax (EBT) 1 | -45.47 | -48.98 | -47.26 | -52.22 | -59.81 | -44.92 | -56.16 | -54.31 | -41.66 | -19.54 | -23.54 | -23.94 | -24.45 | -25.13 | - |
| Net income 1 | -45.47 | -48.98 | -47.26 | -52.22 | -59.81 | -44.92 | -56.16 | -54.31 | -41.66 | -19.54 | -22.33 | -22.56 | -22.91 | -23.32 | - |
| Net margin | -413,372.73% | -445,300% | -2,321.12% | -1,218.93% | -1,073.23% | -305.86% | -719.85% | -509.73% | -541.13% | -182.64% | -262.65% | -259.13% | -258% | -256.49% | - |
| EPS 2 | -0.6300 | -0.6800 | -0.5900 | -0.5500 | -0.6100 | -0.4400 | -0.5200 | -0.4700 | -0.3500 | -0.1600 | -0.1845 | -0.1842 | -0.1819 | -0.1832 | -0.2300 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/9/21 | 2/28/22 | 5/9/22 | 8/8/22 | 11/7/22 | 2/28/23 | 5/9/23 | 8/8/23 | 11/7/23 | 2/28/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 61.7 | 255 | 153 | 281 | 181 | 110 | 23.7 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -68.3 | -75.2 | -141 | -50.4 | -171 | -67 | -85.5 | -89 |
| ROE (net income / shareholders' equity) | -36% | -57.5% | -97.2% | -191% | -266% | -23.4% | - | - |
| ROA (Net income/ Total Assets) | -26.2% | -46.2% | -70.9% | -75.6% | -61.3% | -55.9% | -102% | - |
| Assets 1 | 107.5 | 190.5 | 239.8 | 270.2 | 280.2 | 149.8 | 95.92 | - |
| Book Value Per Share | 1.800 | 3.710 | 1.650 | 0.9800 | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 0.61 | 0.47 | 0.65 | 2.2 | 2.17 | 2.89 | 2.46 | 1.32 |
| Capex / Sales | 1.44% | 57.13% | 1,506.98% | 8.27% | 5.88% | 7.4% | 7.39% | 4.19% |
| Announcement Date | 2/28/20 | 2/26/21 | 2/28/22 | 2/28/23 | 2/28/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
3.16
USD
Average target price
6.5
USD
Spread / Average Target
+105.70%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +34.91% | 387M | |
| -3.18% | 102B | |
| +1.74% | 96.29B | |
| +2.13% | 22.18B | |
| -15.73% | 21.2B | |
| -9.21% | 18.31B | |
| -39.98% | 17.38B | |
| -15.75% | 16.36B | |
| +4.80% | 13.97B | |
| +32.32% | 12.17B |
- Stock Market
- Equities
- MRSN Stock
- Financials Mersana Therapeutics, Inc.
